靶向药物治疗肺动脉高压的研究进展  

Research Progress of Targeted Drug Therapy for Pulmonary Hypertension

作　　者：张洪庆 牛海文 刘昕颖 李雨露 罗琴[1] ZHANG Hongqing;NIU Haiwen;LIU Xinying;LI Yulu;LUO Qin(Department of Respiratory and Neurology,Affiliated Tumor Hospital of Xinjiang Medical University,Urumqi 830011,China)

机构地区：[1]新疆医科大学附属肿瘤医院呼吸神经内科,乌鲁木齐830011

出　　处：《医学综述》2025年第5期611-617,共7页Medical Recapitulate

基　　金：新疆维吾尔自治区自然科学基金(2022D01D74)。

摘　　要：肺动脉高压(PH)是一种慢性、进行性的肺血管系统紊乱疾病,是一种致命的疾病。PH发病机制复杂,基因调控、免疫炎症反应激活、神经激素失衡、线粒体功能障碍、DNA损伤及铁缺乏等均在其中发挥关键作用。随着前列环素类似物、内皮素受体拮抗剂、磷酸二酯酶5抑制剂三大经典靶向药物的出现,患者的生存年限显著延长,生存质量大幅度提升,但仍有大量PH患者对三大经典靶向药物表现出低敏感性,致使治疗效果难以达到预期。PH仍具有高患病率和死亡率,并且在PH靶向药物的研究领域仍存在较多空白。因此,未来需进一步加大新型靶向药物的研发力度,以为PH患者开辟更精准、高效的治疗途径。Pulmonary hypertension(PH)is a chronic and progressive disorder of the pulmonary vascular system and is a fatal disease.The pathogenesis of PH is complex,with gene regulation,activation of immune-inflammatory responses,imbalance of neurohormones,mitochondrial dysfunction,DNA damage and iron deficiency all playing key roles in it.With the emergence of three classic targeted drugs,namely prostacyclin analogs,endothelin receptor antagonists and phosphodiesterase 5 inhibitors,the survival years of the patients have been significantly prolonged and the quality of life has been greatly improved.However,a large number of PH patients still show low sensitivity to these three classic targeted drugs,making it difficult to reach the expected therapeutic effect.PH still has a high incidence and mortality rate,and there are still many gaps in the research field of PH targeted drugs.Therefore,it is necessary to further intensify the research and development of new targeted drugs in the future,so as to open up more precise and efficient treatment approaches for PH patients.

关 键 词：肺动脉高压 药物治疗 靶向制剂 

分 类 号：R543.2[医药卫生—心血管疾病]